See related research by Yang *et al.*, <http://ccforum.com/content/16/1/R9>

In the present issue of *Critical Care*, Yang and colleagues report on the effects of ethyl pyruvate (EP) during acetaminophen intoxication-induced hepatotoxicity \[[@B1]\]. Two hours after an acetaminophen challenge, mice received vehicle or EP every 8 hours for a total of 24 or 48 hours. In a fourth experiment, treatment was started at 24 hours post acetaminophen only. The major findings were that EP attenuated the biochemical and histological markers of liver damage when the treatment was initiated early and maintained over 24 hours only, and that both delayed and prolonged treatments even aggravated organ injury. Interestingly, prolonged treatment coincided not only with decreased expression of cellular cyclin D~1~, a marker of liver cell regeneration, but also with reduced serum levels of TNFα. The authors conclude that despite the well-established beneficial effect of early and anti-inflammatory and antioxidant therapy after acetaminophen intoxication, prolonged treatment is likely to impair hepatocyte regeneration.

Why did the authors choose EP? First, the main author\'s group had previously demonstrated that EP protected against liver injury resulting from alcohol overdose, bile duct ligation-induced cholestasis, and acute pancreatitis, thus confirming its beneficial effects in murine shock states - for example, hemorrhage \[[@B2]\] or sepsis \[[@B3],[@B4]\]. Second, acetaminophen intoxication-induced hepatoxicity results from the formation of the toxic metabolite *N*-acetyl-*p*-benzoquinone imine, which causes severe oxidative stress-related cell damage due to depletion of glutathione. The glutathione precursor *N*-acetylcysteine (NAC) is therefore currently the antidote of choice for the treatment of acetaminophen overdose. However, the authors had previously demonstrated that prolonged NAC administration aggravated liver damage and impaired hepatocellular regeneration \[[@B5]\]. Consequently, they now tested a compound with comparable anti-inflammatory and antioxidant properties. In fact, beside its role as an intermediate glucose metabolite, pyruvate *per se*is well established as an oxygen radical scavenger with anti-inflammatory properties, resulting from the inhibition of TNFα and IL-6 production, the attenuated activation of NF-κB, cyclooxygenase-2 and the inducible isoform of nitric oxide synthase, and the reduction of circulating high-mobility group protein B-1 levels \[[@B6],[@B7]\]. Pyruvate, however, is unstable in aqueous solutions due to a rapid aldol-like condensation reaction forming parapyruvate, a potent inhibitor of the Krebs cycle blocking the α-ketoglutaric dehydrogenase \[[@B7]\]. This problem can be circumvented by using the ethanol ester of pyruvate (that is, EP) - the effects of which qualitatively resemble that of pyruvate, but which only require molar doses that are lower by one to two orders of magnitude \[[@B7]\]. In addition to the properties of pyruvate, EP also exerts anti-apoptotic effects, increases heme oxygenase-1 expression, attenuates peroxynitrite-related DNA damage, and stabilizes the hypoxia-inducible factor 1α via stimulation of the Krebs cycle.

What do we learn from the study by Yang and colleagues? The authors confirm their previous findings that some degree of inflammation seems to be crucial for hepatocyte regeneration after acetaminophen intoxication. Unfortunately, the mechanisms responsible for their observation remain unclear: no information on high-mobility group protein B-1 concentrations is provided, one of the major targets of EP \[[@B3],[@B7]\], which also assumes particular importance for acetaminophen hepatotoxicity \[[@B8]\]. In their previous study, the authors showed that the impaired liver cell recovery resulting from prolonged NAC treatment was associated with attenuated NF-κB activation \[[@B5]\]. There are no data on NF-κB activation either, and the authors therefore missed the opportunity of further elucidating the friend and foe character of NF-κB activation and its modulation by EP, respectively, in shock states. Su and colleagues showed in murine endotoxemia that EP doses ranging from 0.01 to 100 mg/kg caused an early (at 3 hours) decrease and a subsequent late (at 9 hours) moderate increase of lung and kidney NF-κB activation ultimately associated with higher mortality \[[@B9]\]. Furthermore, the second major property of EP - that is, its role as an antioxidant and, consequently, its impact on oxidative stress - remains a matter of debate. The authors did not find any intergroup differences for tissue malondialdehyde concentrations, a marker of lipid peroxidation, but the activities of antioxidant enzymes (for example, superoxide dismutase, catalase, glutathione peroxidase) were not assessed. Finally, there are no data on glutathione depletion, which, however is referred to as the key mechanism of acetaminophen hepatotoxicity.

Which conclusions can be drawn from the study by Yang and colleagues? The authors have the merit of high-lighting the time and dose dependency of any antioxidant administration for acetaminophen intoxication, thus confirming the need for biomarkers that would allow monitoring of liver regeneration and, thus, determination of the tipping point when treatment should be withdrawn \[[@B10]\]. Moreover, the authors add another piece to the puzzling fate of EP in the treatment of the critically ill. Clearly, it is a tempting perspective to have a resuscitation fluid with a \'twist of an anti-inflammatory antioxidant\' \[[@B11]\], but the authors\' current and previous studies on NAC are exemplary for the equivocal effects of antioxidants - that is, the antioxidant paradox \[[@B12]\]: depending on transition metal release, any non-enzymatic antioxidant can become a pro-oxidant and thereby worsen damage. Previously, Magder elegantly highlighted this dilemma: depending on their type, cellular source, and biological target, \'we need to regulate reactive oxygen species, not eradicate them\' \[[@B13]\]. In this context, the role of EP is still not well defined: despite the unanimous data from (mostly unresuscitated) rodent models, the findings in clinically more relevant, resuscitated large animal models are controversial - both beneficial effects \[[@B14]-[@B16]\] and lacking efficacy \[[@B17],[@B18]\] were reported. The only clinical study available demonstrated that EP was safe when administered after induction of anesthesia for high-risk cardiac surgery, but did not confer any benefit with respect to mortality and morbidity as assessed by the duration of mechanical ventilation, the incidence of acute kidney injury, or the need for hemodynamic support \[[@B19]\].
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